Included in the formulation
АТХ:A.04.A.D Other antiemetic drugs
Pharmacodynamics:Moxastine - blocker H1-gistaminovyh receptors. It has sedative and M-cholinoblocking properties. Moxastine reduces the excitability of the emetic center, as well as chemoreceptor trigger zone, which leads to a decrease in the body's response to signals that in susceptible people lead to violations of autonomic functions leading to vomiting, nausea.
Caffeine is an inhibitor of phosphodiesterase, a central stimulant. In this combination acts as an auxiliary component, which reduces the hypnotic and sedative effect of moxastine.
Pharmacokinetics:The drug starts in 10-15 minutes and lasts up to 2 hours.
Moxastine is rapidly absorbed from the gastrointestinal tract, distributed evenly and quickly in all tissues of the body. The relative bioavailability of moxastin of theoclonide by oral administration is 55%. Maximum concentration in the blood plasma is reached 45-70 minutes after ingestion. Metabolized in the liver, excreted by the kidneys and gastrointestinal tract. The half-life is 4-8 hours.
Caffeine is rapidly absorbed from the gastrointestinal tract. Maximum concentration through 50-75 minutes after ingestion. The connection with plasma proteins is from 25 to 36%, metabolized in the liver, excreted by the kidneys, the half-life is 3-7 hours.
Indications:Prevention of nausea and vomiting in motion sickness, arising when using vehicles (car, train, plane, ship). Treatment and prevention of vertigo of various etiologies (including with Meniere's disease, impaired vestibular apparatus).
VIII.H80-H83.H81 Violations of the vestibular function
VIII.H80-H83.H81.0 Ménière's disease
XVIII.R10-R19.R11 Nausea and vomiting
XIX.T66-T78.T75.3 Motion Slicking
Contraindications:Closed-angle glaucoma.
Hyperplasia of the prostate.
Pregnancy.
Lactation period.
Children under 3 years.
Hypersensitivity to the components of the drug.
Due to the presence of lactose in patients with rare hereditary diseases, such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption, the drug is contraindicated.
Pregnancy and lactation:Category FDA - X. Contraindicated during pregnancy and lactation.
Dosing and Administration:Orally 1 tablet (25 mg of moxastine, 30 mg of caffeine) an hour before meals, 0.5-1 tablet every 2-3 hours during the trip / flight.
For immediate relief of nausea / vomiting - 2 tablets at once, then 0.5-2 tablets at short intervals before the onset of relief.
Children under 6 years - a quarter of the pill.
Children under 15 years quarter / half a tablet.
At a dizziness: up to 8 tablets during day in some receptions.
Side effects:On the part of the nervous system: decreased mood, weakness, drowsiness, inhibition, impaired concentration, visual impairment (paralysis of accommodation).
From the digestive system: diarrhea, constipation, abdominal pain, dryness in pt.
From the cardiovascular system: tachycardia, lowering blood pressure.
Allergic reactions: rash, itching, skin hyperemia.
Overdose:Drowsiness, dizziness, loss of consciousness, weakness. Treatment: Activated carbon, gastric lavage, symptomatic therapy.
Interaction:The drug enhances the effect of sleeping pills, antipsychotic drugs (neuroleptics), ethyl alcohol, anxiolytics, ethanol, antispasmodics and sympatholytic drugs; reduces the effect of indirect anticoagulants, oral hypoglycemic drugs, phenytoin,glucocorticosteroids and hormonal contraceptives.
MAO inhibitors and acetylcholinesterase inhibitors increase, and barbiturates and pyrazolone derivatives decrease the effectiveness of the drug.
Special instructions:Impact on the ability to drive vehicles and manage mechanisms
The drug can reduce the ability to concentrate, so the drug should not be taken when performing work that requires increased attention and rapid psychomotor reactions (including drivers and pilots before the planned trip or flight).